All In Biotech

Drug Trial Radar · NCT01555463

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea

Last checked: Nov 19, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 961 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

961

Actual

Start

Sep 2012

Primary completion

Jan 2014

Study completion Jan 2014

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Mar 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.

Conditions

  • Papulopustular Rosacea

Interventions

  • Azelaic acid foam, 15% (BAY39-6251)Drug

    Azelaic acid twice daily topical application

  • Vehicle foamDrug

    twice daily topical application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward)Time frame: At end of treatment (LOCF), up to 12 weeks
  2. Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF)Time frame: Baseline and end of treatment (LOCF), up to 12 weeks

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Fremont, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Ana, California

  • Site not named

    Santa Monica, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miramar, Florida

  • Site not named

    Ormond Beach, Florida

  • Site not named

    Saint Augustine, Florida

  • Site not named

    Buffalo Grove, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Plainfield, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Richmond, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Warren, Michigan

  • Site not named

    West Bloomfield, Michigan

  • Site not named

    Fridley, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Las Vegas, Nevada

  • Site not named

    East Windsor, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Stony Brook, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    High Point, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Winston-Salem, North Carolina

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.